Explore the world of psychedelic research

Papers | Trials | Reports | Events

Access our comprehensive database & reports to stay informed about
the latest developments as psychedelics move from trials to treatments

Inawe Psymposium 2025

Psymposium Madrid 2025 (2–4 Oct): experts gather at ICOMEM to discuss neuroscience, clinical data, and policy for psychedelic therapies.

Continue Reading

Published: 2025-06-13

IV International Conference on Psychedelics

Fuertedélica 2025 marks the fourth edition of our international conference, bringing together researchers, practitioners, and enthusiasts to explore the latest developments in psychedelic studies.

Continue Reading

Published: 2025-06-08

Psychedelic Research Recap May 2025

Psychedelic research in May 2025 shows ketamine saves healthcare costs, esketamine remains safe long-term, and these therapies work differently than expected.

Continue Reading

Category: Uncategorized

Published: 2025-06-08

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

This randomised, waitlist-controlled exploratory study (n=29) of psychedelic-naïve clergy delivered two supported psilocybin sessions (20mg/70kg followed a month later by 20-30mg/70kg). Six months after screening (and still evident 16 months later) the psilocybin group showed sustained improvements in religious practice, leadership effectiveness and overall well-being, with 96 % ranking at least one session among their five most spiritually significant life events and no serious adverse events despite 46 % describing the experience as among their five most challenging.

Continue Reading

Category: Papers

Published: 2025-06-03

Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study

This cost-utility analysis, alongside a randomized controlled trial (n=174), compared subcutaneous ketamine (twice-weekly for 4 weeks) with midazolam in treatment-resistant depression. Including midazolam costs, ketamine raised QALYs (0.435 vs 0.352) and was dominant with an 89–91 % chance of costing < $50 000/QALY, but once these comparator costs were excluded ketamine was no longer cost-effective (ICER ≈ $108 500–$251 250/QALY, ≤ 5 % probability).

Continue Reading

Category: Papers

Published: 2025-06-03

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa

This case study (n=2) of an open-label pilot study (n=10) explores psilocybin-assisted psychotherapy for women with anorexia nervosa (AN or partial remission). Two participants experienced the therapeutic emergence of previously dissociated traumatic memories, leading to remission of AN symptoms and meaningful weight gain at 3-month follow-up.

Continue Reading

Category: Papers

Published: 2025-05-29

Impact analysis of expanded access to ketamine for treatment-resistant depression

This population-level Markov simulation study (n=350,000 initial patients + 11,296 annually) models the economic impacts of intravenous ketamine versus ECT for treatment-resistant depression over 5 years. The model projects annual societal savings of $828.2 million ($95.3M to patients, $743.7M to payers) with expanded ketamine access, though with an added $10.8M annual caregiver burden.

Continue Reading

Category: Papers

Published: 2025-05-29

Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis

This pharmacovigilance analysis (n=751) examines suspected adverse reactions (SARs) to esketamine nasal spray (Spravato) reported in the EudraVigilance database across European countries. The study identifies increased blood pressure (15.4%) and dissociation (15%) as the most common SARs, with data suggesting a potentially higher risk of suicidality with esketamine compared to fluoxetine and venlafaxine, prompting recommendations for careful monitoring of patients with a history of suicidal ideation.

Continue Reading

Category: Papers

Published: 2025-05-29

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study

This randomized, double-blind, placebo-controlled crossover study (n=20) tests the bioequivalence and oral bioavailability of LSD base and tartrate in various formulations (ethanolic solution, watery solution, dissolvable tablet, and IV). All oral formulations were bioequivalent with 80% absolute oral bioavailability. IV LSD produced stronger subjective effects, including more ego dissolution and anxiety.

Continue Reading

Category: Papers

Published: 2025-05-29

Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial

This randomised, double-blind, placebo-controlled single ascending dose study (n=29) tested prolonged intravenous DMT administration (30-s bolus (1.5-7.5mg) + 6-h infusion (4.4-33.3nl/ml)) in healthy volunteers. It found the treatment to be safe, with only mild, self-limiting adverse events, and observed mild psychedelic effects, reduced attention and stability, and decreased occipital alpha EEG power at higher doses, supporting further investigation in stroke recovery contexts.

Continue Reading

Category: Papers

Published: 2025-05-14

Search

partners

Explore Blossom’s Resources

Interconnected & Contextualized Databases

Discover the most relevant papers, trials, events, companies, and people in our extensive collection of over 5,000 entries and 100,000 data points.

Explore Databases

Our interconnected databases allow you to uncover valuable insights and connections in psychedelic research.

Well-Researched Reports

Navigate the complex psychedelic landscape with our meticulously researched reports, covering 18 essential topics, 14 compounds, and 20 countries.

Explore Reports

Our reports provide a comprehensive overview of the current state and future potential of psychedelics.

Timely Insights

Stay informed about the most recent developments in psychedelic research and implementation with our timely articles and updates.

Explore Insights

Our insights cover a wide range of topics, from groundbreaking studies to regulatory changes and industry trends.

Are you new to psychedelics as medicine? Start with our overview →

Subscribe to The Bloom newsletter

Stay at the forefront of the psychedelic revolution with our weekly email, sent every Tuesday. Packed with the latest research breakthroughs, industry news, and actionable insights, The Bloom newsletter is your essential guide to the world of psychedelics.

Join a growing community of over 3,000 researchers, practitioners, and enthusiasts who rely on The Bloom for accurate, timely, and relevant information.

Stay up-to-date with psychedelic research

Free | Blossom Insider

Weekly psychedelic research newsletter
Unlimited browsing on Blossom
2000+ Research Papers (short summaries)

Join

Blossom Pro

Unlimited access for one account
Full reports & extended research summaries
Personal profile priority updates
chatBlossom (our chat interface, in development)

Learn More

Cancel anytime

Blossom Business

Unlimited access for up to ten accounts
All Pro membership benefits, Plus:
Company profile priority updates
Connect via API (show/remix our data on your platform)

Learn More

Cancel anytime

partners

“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”

Josh Hardman

Founder, Psychedelic Alpha

“The work that Floris and the Blossom team have done to document, organise and synthesise the emerging psychedelic research has helped me stay up to date with this fast-changing landscape. The Bloom newsletter and databases are indispensable resources for anyone who wants to understand the psychedelic science and medicine landscape.”

Zach Heighney

Founder, The Trip Report

partners

Explore Our Comprehensive Psychedelic Reports

Discover a wealth of knowledge in our comprehensive psychedelic reports.

“It is wonderful to receive the Bloom newsletter summarising the latest psychedelics research. With so many exciting studies in the psychedelic space, it can be hard to keep up!”

Anne Katrin Schlag

Acting CEO & Head of Research, Drug Science

“Blossom is my go-to resource for the latest in research. It’s the only site to which I refer people who want a comprehensive search for and thoroughgoing analysis of psychedelic studies and papers.”

Rick Strassman

Clinical Associate Professor of Psychiatry, University of New Mexico School of Medicine
Author, DMT: The Spirit Molecule

Embark on a Journey of Personal Transformation with FLO Coaching

FLO Coaching

FLO Coaching, our sister company, offers a personal touch to psychedelic-assisted growth, complementing Blossom’s mission to drive big-picture changes in the psychedelic space.

Founded by Floris, the creator of Blossom, and his wife, FLO Coaching provides one-on-one coaching sessions with psychedelic substances, all within the legal boundaries of The Netherlands. We create a safe and supportive space for you to explore your inner self, overcome obstacles, and grow in ways you never thought possible. At FLO Coaching, we combine cutting-edge research with a personalized approach, tailoring each session to your unique needs and goals.